Systemic therapy for bone sarcomas

David C. Portnoy, Vanderwalde Ari

Research output: Contribution to journalReview article

Abstract

Bone sarcomas comprise less than 0.2% of all malignancies and are divided into several subtypes with varying sensitivities to systemic therapy. While the role of adjuvant chemotherapy in the management of soft-tissue sarcomas is controversial, perioperative chemotherapy has greatly improved the survival of nonmetastatic Ewing sarcoma and osteosarcoma. However, metastatic unresectable Ewing sarcoma and osteosarcoma are still associated with a poor prognosis. Giant cell tumor of bone and chordoma are refractory to conventional cytotoxic chemotherapy, but in recent years targeted therapy has been shown to be able to provide a degree of control of unresectable disease. Conventional chondrosarcoma remains refractory to systemic therapy, although the less common subtypes, dedifferentiated and mesenchymal chondrosarcomas, can be sensitive to chemotherapy but still have a poor prognosis.

Original languageEnglish (US)
Pages (from-to)587-592
Number of pages6
JournalCurrent Orthopaedic Practice
Volume27
Issue number6
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Sarcoma
Ewing's Sarcoma
Osteosarcoma
Bone and Bones
Drug Therapy
Mesenchymal Chondrosarcoma
Giant Cell Tumor of Bone
Chordoma
Chondrosarcoma
Adjuvant Chemotherapy
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine

Cite this

Systemic therapy for bone sarcomas. / Portnoy, David C.; Ari, Vanderwalde.

In: Current Orthopaedic Practice, Vol. 27, No. 6, 01.01.2016, p. 587-592.

Research output: Contribution to journalReview article

Portnoy, David C. ; Ari, Vanderwalde. / Systemic therapy for bone sarcomas. In: Current Orthopaedic Practice. 2016 ; Vol. 27, No. 6. pp. 587-592.
@article{9fb67fe7591e469e8f48b0df994c0874,
title = "Systemic therapy for bone sarcomas",
abstract = "Bone sarcomas comprise less than 0.2{\%} of all malignancies and are divided into several subtypes with varying sensitivities to systemic therapy. While the role of adjuvant chemotherapy in the management of soft-tissue sarcomas is controversial, perioperative chemotherapy has greatly improved the survival of nonmetastatic Ewing sarcoma and osteosarcoma. However, metastatic unresectable Ewing sarcoma and osteosarcoma are still associated with a poor prognosis. Giant cell tumor of bone and chordoma are refractory to conventional cytotoxic chemotherapy, but in recent years targeted therapy has been shown to be able to provide a degree of control of unresectable disease. Conventional chondrosarcoma remains refractory to systemic therapy, although the less common subtypes, dedifferentiated and mesenchymal chondrosarcomas, can be sensitive to chemotherapy but still have a poor prognosis.",
author = "Portnoy, {David C.} and Vanderwalde Ari",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/BCO.0000000000000442",
language = "English (US)",
volume = "27",
pages = "587--592",
journal = "Current Orthopaedic Practice",
issn = "1940-7041",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Systemic therapy for bone sarcomas

AU - Portnoy, David C.

AU - Ari, Vanderwalde

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Bone sarcomas comprise less than 0.2% of all malignancies and are divided into several subtypes with varying sensitivities to systemic therapy. While the role of adjuvant chemotherapy in the management of soft-tissue sarcomas is controversial, perioperative chemotherapy has greatly improved the survival of nonmetastatic Ewing sarcoma and osteosarcoma. However, metastatic unresectable Ewing sarcoma and osteosarcoma are still associated with a poor prognosis. Giant cell tumor of bone and chordoma are refractory to conventional cytotoxic chemotherapy, but in recent years targeted therapy has been shown to be able to provide a degree of control of unresectable disease. Conventional chondrosarcoma remains refractory to systemic therapy, although the less common subtypes, dedifferentiated and mesenchymal chondrosarcomas, can be sensitive to chemotherapy but still have a poor prognosis.

AB - Bone sarcomas comprise less than 0.2% of all malignancies and are divided into several subtypes with varying sensitivities to systemic therapy. While the role of adjuvant chemotherapy in the management of soft-tissue sarcomas is controversial, perioperative chemotherapy has greatly improved the survival of nonmetastatic Ewing sarcoma and osteosarcoma. However, metastatic unresectable Ewing sarcoma and osteosarcoma are still associated with a poor prognosis. Giant cell tumor of bone and chordoma are refractory to conventional cytotoxic chemotherapy, but in recent years targeted therapy has been shown to be able to provide a degree of control of unresectable disease. Conventional chondrosarcoma remains refractory to systemic therapy, although the less common subtypes, dedifferentiated and mesenchymal chondrosarcomas, can be sensitive to chemotherapy but still have a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85010410369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010410369&partnerID=8YFLogxK

U2 - 10.1097/BCO.0000000000000442

DO - 10.1097/BCO.0000000000000442

M3 - Review article

AN - SCOPUS:85010410369

VL - 27

SP - 587

EP - 592

JO - Current Orthopaedic Practice

JF - Current Orthopaedic Practice

SN - 1940-7041

IS - 6

ER -